TY - BOOK ID - 146021016 TI - Cannabis : Neuropsychiatry and Its Effects on Brain and Behavior AU - Colizzi, Marco AU - Bhattacharyya, Sagnik PY - 2021 PB - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute DB - UniCat KW - Medicine KW - Neurosciences KW - delta-9-tetrahydrocannabinol KW - placebo KW - cannabis-associated psychosis KW - schizophrenia KW - BDNF KW - CB1 KW - CB2 KW - episodic memory KW - exercise KW - African American KW - black KW - older adult KW - marijuana use KW - cannabis use disorder KW - cue reactivity KW - craving KW - inhibitory control KW - frontal alpha asymmetry KW - EEG KW - cannabinoids KW - cannabis use KW - psychotic disorder KW - genetics KW - age of onset KW - clinical high risk KW - cannabis KW - memory KW - functional magnetic resonance imaging KW - THC KW - systematic review KW - gyrification KW - surface area KW - cortical surface structure KW - aerobic fitness KW - gender KW - endocannabinoid system KW - executive functions KW - problematic cannabis use KW - triple network KW - EEG functional connectivity KW - eLORETA KW - resting state KW - Delta-9-tetrahydrocannabinol KW - dronabinol KW - marijuana KW - randomized controlled trial KW - opioids KW - traumatic injury KW - alcohol KW - adolescents KW - fMRI KW - interoception KW - negative reinforcement KW - migraine: chronic pain KW - triptans KW - disability UR - https://www.unicat.be/uniCat?func=search&query=sysid:146021016 AB - Over the years, there has been increasing interest into the public health impact of cannabis use, especially by young adults. This follows the evidence of a growing prevalence of regular cannabis use worldwide, with approximately 200 million users. Recreational cannabis use, especially a frequent use of products with high levels of its main psychoactive ingredient delta-9-tetrahydrocannabinol (Δ 9-THC), can cause dependence and have transient and long-lasting detrimental mental health effects, also negatively impacting cognitive processing and brain function and metabolism. In regular users, the development of tolerance to some of the effects of cannabis, especially the pleasurable ones, may lead to progressively heavier use in order to obtain the same effects in terms of their intensity, with higher health risks. However, the Cannabis Sativa plant contains different chemicals with different potential effects. In this regard, cannabidiol has gained interest because of its potential therapeutic properties, in line with evidence that CBD and Δ9-THC may exhibit opposite effects at the cannabinoid receptor type 1 (CB1), Δ9-THC being a partial agonist and CBD an antagonist/inverse agonist. Different cannabinoids may modulate human brain function and behavior in different ways, with different risk–benefit profiles. ER -